Merus N.V.

44.52
-0.31 (-0.69%)
At close: Mar 28, 2025, 3:59 PM
44.01
-1.16%
After-hours: Mar 28, 2025, 05:31 PM EDT
-0.69%
Bid 37.78
Market Cap 3.08B
Revenue (ttm) 38.87M
Net Income (ttm) -231.65M
EPS (ttm) -3.35
PE Ratio (ttm) -13.29
Forward PE -10.77
Analyst Buy
Ask 44.52
Volume 342,136
Avg. Volume (20D) 621,451
Open 44.85
Previous Close 44.83
Day's Range 44.00 - 45.09
52-Week Range 37.77 - 61.61
Beta 1.15

About MRUS

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also de...

Industry Biotechnology
Sector Healthcare
IPO Date May 19, 2016
Employees 260
Stock Exchange NASDAQ
Ticker Symbol MRUS
Full Company Profile

Analyst Forecast

According to 12 analyst ratings, the average rating for MRUS stock is "Buy." The 12-month stock price forecast is $84.5, which is an increase of 89.78% from the latest price.

Stock Forecasts

Next Earnings Release

Merus N.V. is scheduled to release its earnings on May 7, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+5.15%
Merus shares are trading higher after the company ... Unlock content with Pro Subscription
2 months ago
-7.75%
Merus shares are trading lower. The company announced a research collaboration and license agreement with Biohaven to co-develop three novel bispecific antibody drug conjugates.